Amarin drug downplayed a conference, says Summer Street

Summer Street says Amarin's Vascepa was downplayed by a company insider at a primary care conference held in Washington DC last week. The firm notes that a member of Amarin’s steering committee said in a lecture that there is no reason to give Vascepa to patients with triglyceride levels below 500 until the outcome trial is complete. Summer Street continues to believe the FDA will not approve Vascepa for triglycerides below 500 until the outcome study is complete.